(Q85242649)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23086225%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

title

Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23086225%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

Katharina M Droege

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23086225%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Philipp S Muether

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23086225%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Manuel M Hermann

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23086225%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Albert Caramoy

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23086225%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Ulrike Viebahn

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23086225%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Bernd Kirchhof

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23086225%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Sascha Fauser

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23086225%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

publication date

20 October 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23086225%20AND%20SRC:MED&resulttype=core&format=json

Graefe's Archive for Clinical and Experimental Ophthalmology

16 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23086225%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

251

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23086225%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23086225%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

1281-1284

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23086225%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00417-012-2177-3

16 February 2020

exact match

0 references

cites work

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2

1 reference

12 December 2020

Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration

1 reference

12 December 2020

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

1 reference

12 December 2020

Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration

1 reference

12 December 2020

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

1 reference

12 December 2020

Ranibizumab for neovascular age-related macular degeneration

1 reference

12 December 2020

[Differences in the treatment of exudative age-related macular degeneration in Germany and Great Britain]

1 reference

12 December 2020

Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity

1 reference

12 December 2020